UCLA Health oncologist Dr. Dennis SlamonPhoto: UCLA
LOS ANGELES (CNS) - UCLA Health oncologist Dr. Dennis Slamon has been awarded the 2024 Szent-Gyorgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research, officials announced Wednesday.
The foundation recognized Slamon for research that helped shape the field of precision medicine in breast cancer and paved the way for the development of other targeted therapies in oncology.
"I am honored and humbled to receive this prestigious award," said Slamon, director of clinical and translational research at the UCLA Health Jonsson Comprehensive Cancer Center and chief of hematology/oncology at the David Geffen School of Medicine at UCLA.
"This recognition is not just for me, but for the countless researchers, clinicians, and especially the brave women who have participated in our clinical trials. Together, we have changed the landscape of breast cancer treatment and continue to work on developing cancer treatments that can move from the bench to the bedside more rapidly."
Slamon first identified the HER2 gene, which is overexpressed in about 25%-30% of breast cancer cases and is associated with a more aggressive form of the disease. This non-inherited genetic change defined a new subtype of breast cancer.
This research and subsequent clinical trials led by Slamon resulted in the development of the breast cancer drug Herceptin, the first gene-based drug to be approved by the U.S. Food and Drug Administration to fight cancer. Since its introduction in 1998, Herceptin has become a cornerstone in the treatment of HER2-positive breast cancer, benefiting millions of women worldwide.
"Dr. Slamon created a new paradigm for modern translational cancer research," said Dr. Michael Teitell, director of the UCLA Health Jonsson Comprehensive Cancer Center. "His discoveries emphasized the importance of targeting the molecular mechanism, not the histology of cancer, which has become the basis for most new cancer treatments. He has inspired physicians and investigators, including myself, to look beyond their existing assumptions to find more effective ways to treat people with cancer."
In addition to Herceptin, Slamon and his team also spearhead the development of the initial targeted inhibitor of CDK-4/6, palbociclib (Ibrance), which was approved by the FDA for women with advanced estrogen receptor-positive, HER-2-negative breast cancer, the most common subtype of the disease.
"Dr. Slamon epitomizes our vision of a Szent-Gyorgyi Prize winner," said Dr. Sujuan Ba, NFCR's president and CEO and co-chair of the 2024 Szent- Gyorgyi Prize Selection Committee. "One of my favorite quotes from our co- founder Albert Szent-Gyorgyi is `to see what others have seen but to think differently than anybody else has thought.' Dr. Slamon has done just this through his research around the amplification of the HER2 gene, which shed even more light on cancer being a genetic disease and paved the way for a completely new set of targeted treatments for breast cancer patients.
"Over time as his research produced more and more positive results for cancer patients, many of his research and medical peers began to adopt the viewpoint of `breast cancer before Dennis and after Dennis.' We could not be more proud to have Dr. Slamon as our 2024 Szent-Gyorgyi Prize winner," Ba added.
The Szent-Gyorgyi Prize has been awarded annually since 2006 to honor an outstanding scientist whose body of work has had a lasting impact on the understanding of cancer, significantly improving or saving the lives of people with the disease.